XLO Q2 2025 Earnings — Xilio Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

XLOXilio Therapeutics, Inc.

$28M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+243.0% YoY

Gross Profit

-$7M-89.6% margin

Operating Income

-$14M-177.7% margin

Net Income

-$16M-196.0% margin

EPS (Diluted)

$-0.16

QoQ Revenue Growth

+175.9%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$15M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$134M

Total Liabilities

$127M

Stockholders' Equity

$7M

Cash & Equivalents

$122M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$2M	+243.0%
Gross Profit	-$7M	$2M	-407.4%
Operating Income	-$14M	-$15M	+2.3%
Net Income	-$16M	-$14M	-13.8%